- Home
- IBIO vs PSTV Comparison
IBIO vs PSTV Comparison
Compare IBIO & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | PSTV |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 46.4M |
| IPO Year | 2009 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IBIO | PSTV |
|---|---|---|
| Price | $2.49 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.75 | ★ $6.75 |
| AVG Volume (30 Days) | 995.4K | ★ 3.9M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | 44.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,824,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $46.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 18.54 |
| 52 Week Low | $0.56 | $0.16 |
| 52 Week High | $5.60 | $2.08 |
Technical Indicators
Market Signals| Indicator | IBIO | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 48.25 |
| Support Level | $0.78 | $0.26 |
| Resistance Level | $3.01 | $0.32 |
| Average True Range (ATR) | 0.27 | 0.03 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 23.46 | 40.14 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).